Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 10/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ACE2 | Q9BYF1 | 7/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6818900 | 0.85 | ALDH1A1 (0.50) | ALDH1A1KMT2A | |
| SCHEMBL714622 | 0.84 | NPC1 (0.46) | ALDH1A1KMT2AACE2L3MBTL1 | |
| SCHEMBL9908470 | 0.83 | ATM (0.47) | ACEMEN1ALDH1A1KMT2AACE2 | |
| SCHEMBL5525818 | 0.82 | ALDH1A1 (0.47) | MEN1ALDH1A1KMT2A | |
| SCHEMBL13508877 | 0.82 | ALDH1A1 (0.49) | ACEALDH1A1ACE2ATML3MBTL1 | |
| SCHEMBL14434719 | 0.81 | ALDH1A1 (0.43) | ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL12949799 | 0.81 | PREP (0.44) | KMT2A | |
| SCHEMBL10605848 | 0.81 | ACE (0.62) | ACEKMT2AATM | |
| SCHEMBL10605836 | 0.81 | ACE (0.62) | ACEKMT2AATM | |
| SCHEMBL7855557 | 0.78 | GPR132 (0.51) | ACEACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2389176-A1 | NOVEL METABOLIC DISEASE THERAPY | The University Of Sydney (AU) | 2011-11-30 | — | — | EP | claimed |
| US-20110253961-A1 | Combined Guardrail and Cable Safety Systems | TRINITY INDUSTRIES, INC. (US) | 2011-10-20 | — | — | US | claimed |
| WO-2010083570-A1 | NOVEL METABOLIC DISEASE THERAPY | THE UNIVERSITY OF SYDNEY (AU) | 2010-07-29 | — | — | WO | claimed |
| US-20100081701-A1 | FAP inhibitors | VANTIA LIMITED (GB) | 2010-04-01 | — | — | US | claimed |
| EP-1919864-A2 | FAP INHIBITORS | Ferring B.V. (NL) | 2008-05-14 | — | — | EP | claimed |
| WO-2007085895-A2 | FAP INHIBITORS | FERRING B.V. (US) | 2007-08-02 | — | — | WO | claimed |
| EP-1760076-A1 | FAP Inhibitors | FERRING B.V. (NL) | 2007-03-07 | — | — | EP | claimed |
| US-8183280-B2 | FAP inhibitors | VANTIA LIMITED (GB) | 2012-05-22 | — | — | US | disclosed |
| US-8183280-B2 | FAP inhibitors | VANTIA LIMITED (GB) | 2012-05-22 | — | — | US | disclosed |
| US-20120053222-A1 | Novel Metabolic Disease Therapy | THE UNIVERSITY OF SYDNEY (AU) | 2012-03-01 | — | — | US | disclosed |
| EP-2389176-A1 | NOVEL METABOLIC DISEASE THERAPY | The University Of Sydney (AU) | 2011-11-30 | — | — | EP | disclosed |
| US-20110253961-A1 | Combined Guardrail and Cable Safety Systems | TRINITY INDUSTRIES, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| WO-2010083570-A1 | NOVEL METABOLIC DISEASE THERAPY | THE UNIVERSITY OF SYDNEY (AU) | 2010-07-29 | — | — | WO | disclosed |
| US-20100081701-A1 | FAP inhibitors | VANTIA LIMITED (GB) | 2010-04-01 | — | — | US | disclosed |
| US-20100081701-A1 | FAP inhibitors | VANTIA LIMITED (GB) | 2010-04-01 | — | — | US | disclosed |
| EP-1919864-A2 | FAP INHIBITORS | Ferring B.V. (NL) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007085895-A2 | FAP INHIBITORS | FERRING B.V. (US) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007085895-A2 | FAP INHIBITORS | FERRING B.V. (US) | 2007-08-02 | — | — | WO | disclosed |
| EP-1760076-A1 | FAP Inhibitors | FERRING B.V. (NL) | 2007-03-07 | — | — | EP | disclosed |
| EP-1760076-A1 | FAP Inhibitors | FERRING B.V. (NL) | 2007-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081701-A1 | FAP inhibitors | FAP, APC, SERPINB1 | ACE 127/4885MEN1 1551/4885ALDH1A1 379/4885 |
| US-20120053222-A1 | Novel Metabolic Disease Therapy | FAP, G6PC1, FBP1 | ACE 191/4885MEN1 2384/4885ALDH1A1 901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.